New drug aims to boost Cancer-Fighting CAR-T cells
NCT ID NCT05075603
Summary
This study tested a drug called NT-I7 in patients with aggressive lymphoma that returned after CAR-T therapy. The main goal was to find a safe dose and see if NT-I7 could help the CAR-T cells last longer and fight the cancer better. The trial involved 17 adults who had already received standard CAR-T treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
City of Hope
Duarte, California, 91010, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.